SCHEDULE 13G/A: Vanguard Group Discloses 9.8% Stake in Crinetics Pharmaceuticals
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, reporting a 9.8% beneficial ownership stake in Crinetics Pharmaceuticals Inc. as of December 31, 2024.
Summary
- The Vanguard Group, a Pennsylvania-based investment adviser, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Crinetics Pharmaceuticals Inc.
- As of December 31, 2024, The Vanguard Group beneficially owns an aggregate of 9,089,391 shares of Crinetics Pharmaceuticals Inc. Common Stock.
- This ownership represents 9.8% of the class of securities.
- Vanguard holds sole dispositive power over 8,819,370 shares and shared dispositive power over 270,021 shares.
- Vanguard holds sole voting power over 0 shares and shared voting power over 164,723 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The document is a standard regulatory disclosure of beneficial ownership. While neutral in tone, the continued significant stake by a major institutional investor like Vanguard can be perceived as a moderately positive signal for the company's stability and investment appeal.
Positives
- The disclosure of a significant stake by a major institutional investor like The Vanguard Group can be viewed as a vote of confidence in Crinetics Pharmaceuticals Inc.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large institutional investor in the biotechnology and pharmaceutical sector. It indicates Vanguard's continued investment in Crinetics Pharmaceuticals Inc., a company operating within this industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date) |
| 01/30/2025 | Date of signature for the Schedule 13G filing |
Keywords
Crinetics Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.